Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the voluntary announcements of Genscript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 8 December 2019 and 9 December 2019. The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce the updated results from the Janssen Pharmaceutical Companies of Johnson & Johnson ("**Janssen**") sponsored Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma. JNJ-4528 is a structurally differentiated CAR-T cell therapy containing a 4-1BB co-stimulatory domain and two BCMA-targeting single-domain antibodies designed to confer avidity.

Longer-term follow-up results from the Phase 1b portion of the study (n=29), to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #8505), show that all patients responded to treatment and that the responses were deep and durable with 86% of patients achieving stringent complete response at a median follow-up time of 11.5 months. In addition, the results showed a 100% overall response rate (ORR), which included 97% of patients achieving a very good partial response or better and 3% achieving a partial response. The median time to first response was 1 month (range, 1-3), and 81% of evaluable patients (n=16) achieved minimal residual disease (MRD)-negative disease status at 10^{-5} or 10^{-6} at the time of first suspected complete response. The 9-month progression free survival rate was 86% and 22 of 29 patients remained alive and progression free at the time of data cut-off. Patients in the study were heavily pre-treated and received a median dose of 0.72×10^6 CAR+ viable T cells/kg.

Patients evaluated received a median of 5 (range, 3-18) prior treatment regimens; 86% were triple-refractory and 28% were penta-refractory.

"The longer-term results for JNJ-4528, as demonstrated through the latest findings from the CARTITUDE-1 study, show the continued treatment effect for heavily pre-treated patients who faced a poor prognosis," said Jesus G. Berdeja, M.D., Director of Myeloma Research, Sarah Cannon Research Institute, and principal study investigator. "We're encouraged by not only the relatively high rate of stringent complete responses, but the strong progression-free survival results seen in these patients."

The most common adverse events (AEs) observed in CARTITUDE-1 were neutropenia (100%) and cytokine release syndrome (CRS) (93%). The median onset of CRS was 7 days (range, 2-12) post-infusion, with a majority of patients experiencing Grade 1-2 CRS and 2 patients experiencing Grade 3 or greater CRS. In patients who experienced Grade 3 and above AEs, the most common were neutropenia (100%), thrombocytopenia (69%), and leukopenia (66%). Neurotoxicity consistent with ICANS was observed in 3 patients (10%) including 1 patient (3%) with ≥ Grade 3 toxicity. There were 3 deaths during the Phase 1b study: 1 due to CRS, 1 due to acute myeloid leukemia (not treatment-related), and 1 due to progressive disease.

The Phase 1b portion of the CARTITUDE-1 study further support the findings from the LEGEND-2 study in China, with both demonstrating deep, durable treatment responses. Legend Biotech Corporation remains committed to working closely with strategic partner and key stakeholders to advance JNJ-4528 through clinical development, in line with the mission to deliver innovative cell therapy options to patients living with cancer.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 14 May 2020

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*